ES2530670T3 - Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo - Google Patents

Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Download PDF

Info

Publication number
ES2530670T3
ES2530670T3 ES08711707T ES08711707T ES2530670T3 ES 2530670 T3 ES2530670 T3 ES 2530670T3 ES 08711707 T ES08711707 T ES 08711707T ES 08711707 T ES08711707 T ES 08711707T ES 2530670 T3 ES2530670 T3 ES 2530670T3
Authority
ES
Spain
Prior art keywords
same
pharmaceutical composition
amino acid
acid sequence
fgf23 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08711707T
Other languages
English (en)
Inventor
Yuji Yamazaki
Itaru Urakawa
Hitoshi Yoshida
Yukiko Aono
Takeyoshi Yamashita
Takashi Shimada
Hisashi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2530670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ES2530670T3 publication Critical patent/ES2530670T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)

Abstract

Anticuerpo frente a FGF23 humano o un fragmento funcional del mismo frente a FGF23 humano, que comprende una secuencia de aminoácidos de cadena pesada que comprende una secuencia de aminoácidos desde Q en la posición 20 hasta S en la posición 136 de SEC ID Nº 12 y una secuencia de aminoácidos de cadena ligera que comprende una secuencia de aminoácidos desde A en la posición 23 hasta K en la posición 128 de SEC ID Nº 14.
ES08711707T 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo Active ES2530670T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007034018 2007-02-14
PCT/JP2008/052918 WO2008099969A1 (ja) 2007-02-14 2008-02-14 抗fgf23抗体及びそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
ES2530670T3 true ES2530670T3 (es) 2015-03-04

Family

ID=39690189

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES08711707T Active ES2530670T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES12170984T Active ES2625823T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
ES17152168T Active ES2811318T3 (es) 2007-02-14 2008-02-14 Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo

Country Status (23)

Country Link
US (4) US7883705B2 (es)
EP (3) EP2128253B1 (es)
JP (1) JP4800396B2 (es)
KR (1) KR101462291B1 (es)
CN (2) CN102702355B (es)
AU (1) AU2008215346B2 (es)
CA (1) CA2677782C (es)
CY (3) CY1118835T1 (es)
DK (3) DK2502996T3 (es)
ES (3) ES2625823T3 (es)
FR (1) FR18C1032I2 (es)
HK (2) HK1140228A1 (es)
HR (2) HRP20170548T1 (es)
HU (3) HUE031728T2 (es)
LT (3) LT2502996T (es)
LU (2) LUC00081I2 (es)
NL (1) NL300945I2 (es)
NO (1) NO2018025I1 (es)
PL (3) PL3181691T3 (es)
PT (3) PT2128253E (es)
SI (2) SI3181691T1 (es)
TW (1) TWI422593B (es)
WO (1) WO2008099969A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100387713C (zh) * 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
ES2331414T3 (es) * 2001-12-28 2010-01-04 Kyowa Hakko Kirin Co Ltd Anticuerpos contra el factor 23 de crecimiento de fibroblastos.
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
AR100689A1 (es) * 2014-06-09 2016-10-26 Ultragenyx Pharmaceutical Inc Control del fosfato sérico para una osificación óptima
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
CN110494561A (zh) 2017-03-30 2019-11-22 希森美康株式会社 抗ApoA1抗体
AU2020253833A1 (en) * 2019-03-29 2021-10-28 Atarga, Llc Anti FGF23 antibody
TW202413406A (zh) * 2022-08-10 2024-04-01 日商協和麒麟股份有限公司 抗fgf23抗體或該抗體片段

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5623587A (en) 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
WO1985003934A1 (en) 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61178926U (es) 1985-04-23 1986-11-08
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5958879A (en) 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6818745B1 (en) 1998-05-18 2004-11-16 University College London Polypeptide hormone phosphatonin
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2709291A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001042451A2 (en) 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
JP2003518944A (ja) 2000-01-05 2003-06-17 ザイモジェネティクス，インコーポレイティド 新規ｆｇｆ相同体ｚｆｇｆ１２
US20030149238A1 (en) 2000-02-14 2003-08-07 Pankaj Agarwal Novel compounds
AU3976701A (en) 2000-02-15 2001-08-27 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20020082205A1 (en) 2000-03-08 2002-06-27 Nobuyuki Itoh Human FGF-23 gene and gene expression products
AU2001245535A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
DE60141582D1 (de) 2000-07-19 2010-04-29 Advanced Res & Tech Inst Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
CN100387713C (zh) 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
WO2002076467A1 (en) 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism
CN1602355A (zh) 2001-04-26 2005-03-30 杰诺瓦有限公司 与人成纤维细胞生长因子有关的组合物
DK1391464T3 (da) * 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
ES2331414T3 (es) 2001-12-28 2010-01-04 Kyowa Hakko Kirin Co Ltd Anticuerpos contra el factor 23 de crecimiento de fibroblastos.
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
WO2004083425A1 (ja) * 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha 歯周病治療剤
AU2005250499B2 (en) * 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
DK1773885T3 (da) * 2004-08-05 2010-08-16 Genentech Inc Humaniserede anti-c-met-antagonister
WO2006028197A1 (ja) * 2004-09-06 2006-03-16 Kirin Beer Kabushiki Kaisha 抗a33抗体
EP1849863A1 (en) 2005-01-21 2007-10-31 Kirin Pharma Kabushiki Kaisha Non-human chimeric animal and use thereof
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
US20100062984A1 (en) * 2007-01-25 2010-03-11 Rajiv Kumar Fgf-23 polypeptides
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
US9290569B2 (en) 2016-03-22
PT3181691T (pt) 2020-08-26
CN101652476A (zh) 2010-02-17
CY2018021I2 (el) 2019-07-10
PL2502996T3 (pl) 2017-07-31
HRP20201266T1 (hr) 2021-02-05
PL2128253T3 (pl) 2015-04-30
ES2811318T3 (es) 2021-03-11
LTC2502996I2 (lt) 2019-05-10
AU2008215346A1 (en) 2008-08-21
NO2018025I1 (no) 2018-08-09
EP2128253A4 (en) 2010-03-10
EP3181691B1 (en) 2020-07-15
CN102702355B (zh) 2014-09-24
TWI422593B (zh) 2014-01-11
JPWO2008099969A1 (ja) 2010-05-27
ES2625823T3 (es) 2017-07-20
TW200902549A (en) 2009-01-16
NL300945I1 (en) 2018-08-15
WO2008099969A1 (ja) 2008-08-21
HUS1800034I1 (hu) 2018-09-28
LTPA2018508I1 (lt) 2018-09-10
EP2128253B1 (en) 2014-12-03
US10202446B2 (en) 2019-02-12
HUE031728T2 (en) 2017-07-28
HUE050517T2 (hu) 2020-12-28
SI2502996T1 (sl) 2017-08-31
CA2677782C (en) 2016-07-26
CA2677782A1 (en) 2008-08-21
KR20090114452A (ko) 2009-11-03
EP2502996A2 (en) 2012-09-26
HRP20170548T1 (hr) 2017-08-25
LUC00082I2 (es) 2018-10-01
DK3181691T3 (da) 2020-08-17
KR101462291B1 (ko) 2014-11-14
US7883705B2 (en) 2011-02-08
NL300945I2 (en) 2020-05-13
LT3181691T (lt) 2020-08-25
CN102702355A (zh) 2012-10-03
US20160159895A1 (en) 2016-06-09
US20190106485A1 (en) 2019-04-11
HK1172917A1 (en) 2013-05-03
FR18C1032I2 (fr) 2019-08-09
US20090148461A1 (en) 2009-06-11
HK1140228A1 (en) 2010-10-08
JP4800396B2 (ja) 2011-10-26
FR18C1032I1 (es) 2018-08-31
EP3181691A1 (en) 2017-06-21
AU2008215346B2 (en) 2013-01-10
CY2018021I1 (el) 2019-07-10
PT2502996T (pt) 2017-05-10
LUC00081I2 (es) 2018-10-01
DK2128253T3 (en) 2015-01-05
PT2128253E (pt) 2015-02-04
PL3181691T3 (pl) 2020-11-02
US20110182913A1 (en) 2011-07-28
CN101652476B (zh) 2012-07-04
CY1118835T1 (el) 2018-01-10
EP2502996B1 (en) 2017-03-29
SI3181691T1 (sl) 2020-09-30
EP2502996A3 (en) 2013-04-10
LT2502996T (lt) 2017-06-26
CY1123240T1 (el) 2021-10-29
EP2128253A1 (en) 2009-12-02
DK2502996T3 (en) 2017-05-08

Similar Documents

Publication Publication Date Title
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
PE20120429A1 (es) Proteinas de enlace de miostatina
ES2585480T3 (es) Anticuerpo anti-NR10 y uso del mismo
CY1120137T1 (el) Ενεσιμα σκευασματα βοτουλινικης τοξινης
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
NL301089I2 (nl) imlifidase
PE20121393A1 (es) Analogo peptidico de oxintomodulina
ES2531385T3 (es) Formulación que comprende un anticuerpo contra la selectina P
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
MX357972B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
ATE497975T1 (de) Il-21-varianten
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
PH12013502192A1 (en) Antibodies against human angiopoietin 2
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR10730A (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
PA8852901A1 (es) Inhibidores de proteina cinasa
EA200701825A1 (ru) Вакцины против хламидиоза
RS53236B (en) BETA-AMYLOIDOSIS PEPTIDES